Navigation ▼

Show simple item record

dc.contributor.advisor Martínez-Olivera, Ramon PD Dr.
dc.contributor.author Schell, Julian Michael
dc.date.accessioned 2015-03-16T08:45:37Z
dc.date.available 2015-04-27T22:50:05Z
dc.date.issued 2015-03-16
dc.identifier.uri http://hdl.handle.net/11858/00-1735-0000-0022-5F80-5
dc.language.iso deu de
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/
dc.subject.ddc 610 de
dc.title Einfluss der Blockade des Kaliumkanals Eag1 durch trizyklische und nicht-trizyklische Antidepressiva auf die Überlebenszeit von Patienten mit Glioblastoma multiforme bzw. Hirnmetastasen und Depression: Eine klinische und immunhistochemische Analyse. de
dc.type doctoralThesis de
dc.title.translated Impact of Eag1 inhibition with tricyclic and non-tricyclic antidepressants on survival in patients with glioblastoma multiforme or brain metastases and depression. Clinical and immunhistochemical analysis. de
dc.contributor.referee Martínez-Olivera, Ramon PD Dr.
dc.date.examination 2015-04-20
dc.description.abstracteng Glioblastoma multiforme (GBM) is a malignant neoplasia with astrocytic respectively oligoastrocytic origin. In adults, it is the most common primary brain tumor. Brain metastases are secondary brain tumors. Mostly, these malignancies are originated from lung and breast cancer or melanoma. Despite multimodal therapies, prognosis of patients with GBM and brain metastases is limited. Reducing of tumor progression by inhibition of molecular marker in tumor cells represents a possibility to increase the prognosis of patients. The voltage-gated potassium channel Eag1 is overexpressed in extracerebral carcinoma associated with overexpression of VEGF and inhibition of p53, resulting in increased tumor progression and worse prognosis. Eag1 was found to be a molecular marker because in vitro inhibition of Eag1 with tricyclic antidepressants or monoclonal antibodies led to reducing of tumor progression. In this study, Eag1 expression in tumor tissue of patients with GBM and brain metastases in combination with impact on survival was analyzed. Moreover, the influence of inhibition of Eag1 with tricyclic and non-tricyclic antidepressants on survival was examined. The results showed that Eag1 is overexpressed in GBM and brain metastases. In brain metastases, overexpression of Eag1 was significantly associated with limited survival time. Respectively, patients with low Eag1 expression had a better prognosis. In this patients, inhibition of Eag1 with tricyclic antidepressants showed a significant longer survival time in addition. However, the results didn't show significant effects on survival in patients with GBM. Our data strongly suggest that Eag1 is a tumor marker in brain metastases and GBM. In patients with brain metastases, Eag1 is a potential prognosis marker and oncotarget for a personalized therapy. de
dc.contributor.coReferee Stühmer, Walter Prof. Dr.
dc.subject.eng Eag1 de
dc.subject.eng Ether-a-go-go 1 de
dc.subject.eng Brain metastases de
dc.subject.eng Glioblastoma multiforme de
dc.identifier.urn urn:nbn:de:gbv:7-11858/00-1735-0000-0022-5F80-5-7
dc.affiliation.institute Medizinische Fakultät de
dc.subject.gokfull Medizin (PPN619874732) de
dc.subject.gokfull Neurologie - Allgemein- und Gesamtdarstellungen (PPN619876247) de
dc.description.embargoed 2015-04-27
dc.identifier.ppn 820336300

Files in this item

This item appears in the following Collection(s)

Show simple item record